Responses

PDF

Value or cost: looking for the wider perspective
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]
Publication Date - String

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Government intervention in pricing has great impact on cost and therefore on value.
    • Sagarika Kamath, Assistant Professor -MBA healthcare program Manipal University
    • Other Contributors:
      • Rajesh Kamath, Assistant Professor-Department of Public health
      • brayal d'souza, Assistant Professor-Department of Public health

    Reading the editorial – “Value or cost: looking for the wider perspective”,the one thing that struck us the most was,when pharmacists determine value,one of the most important variables that they take into account is the monetary cost of the intervention,say antibiotics.This raised several questions in our minds.What if the antibiotics on the hospital formulary were priced at a point that their use in certain situations seemed unjustified to pharmacists,but would seem perfectly justified at lower price points?What if generics,available at a fraction of the price of the branded variety,were used in place of the brands?It seems to us that they would most certainly impact the way that “value” is calculated for that particular scenario.What if the pharmacist knew a perfectly good enough generic,but hospital policy allowed procurement,and hence prescribing of,only a more expensive brand?
    When hospital pharmacists try to assess the value of a new health technology,we feel that they would be well served if they took a long,hard look at the evidence.Sometimes claims might not be very genuine.And this could place heavy costs on the patients.A very contemporary example would be the pricing of cardiac stents. Cardiac stents are sold at a 300 to 400 percent mark up to Indian patients.A stent that costs Rs.20,000(Euro 284) if bought from a vendor would miraculously cost Rs.160,000(Euro 2273)at the hospital pharmacy,all other charges being separate.1The patient is not given the o...

    Show More
    Conflict of Interest:
    None declared.